Clinical Trials in Detroit

Showing 6641-6660 of 14,997 trials

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

NCT02323113

The purpose of the Phase 1b dose finding phase is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-659 in participants with relapsed or refractory AML. The purpose of the Phase 2 expansion phase is to evaluate preliminary efficacy of TAK-659 in relapsed or refractory AML as measured by overall response rate (ORR).

Acute Myelogenous Leukemia

Calithera Biosciences, Inc43 participantsStarted Mar 2015

Birmingham, Alabama, United States • Chicago, Illinois, United States • Niles, Illinois, United States +14 more locations

COMPLETED< 1 mile

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

NCT03739307

This is a five year multi-site, cross sectional, observational study designed to examine chronic pain and pain treatment after moderate to severe TBI.

Traumatic Brain InjuryPain

Craig Hospital3,805 participantsStarted May 2019

Birmingham, Alabama, United States • Englewood, Colorado, United States • Tampa, Florida, United States +10 more locations

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

Find Trials by Condition in Detroit

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Sargramostim Use in COVID-19 to Recover Patient Health

A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

Validation of a Salivary miRNA Diagnostic Test for ASD

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

A Study of Modified Stem Cells in Stable Ischemic Stroke

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Improving Quality by Maintaining Accurate Problems in the EHR

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

Peripheral Nerve Stimulation Therapy for Atrial Fibrillation

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis